Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - caspofungin - powder for concentrate for solution for infusion - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - caspofungin - pdr/conc/soln for infus - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - caspofungin - pdr/conc/soln for infus - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

demo s.a. - caspofungin - powder for concentrate for solution for infusion - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

demo s.a. - caspofungin - powder for concentrate for solution for infusion - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - caspofungin - powder for concentrate for solution for infusion - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - caspofungin - powder for concentrate for solution for infusion - 70 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - caspofungin - pdr/conc/soln for infus - 50 milligram(s) - other antimycotics for systemic use; caspofungin

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - caspofungin - pdr/conc/soln for infus - 70 milligram(s) - other antimycotics for systemic use; caspofungin

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofungin acetate - candidiasis; aspergillosis - antimycotics for systemic use - treatment of invasive candidiasis in adult or paediatric patients.treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and/or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.